Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Adolescent
Adult
Aged
Aged, 80 and over
Anticonvulsants
/ adverse effects
Carbamazepine
/ adverse effects
Clinical Studies as Topic
Dibenzazepines
/ adverse effects
Drug Substitution
Drug-Related Side Effects and Adverse Reactions
Europe
Female
Follow-Up Studies
Humans
Male
Middle Aged
Outcome Assessment, Health Care
/ statistics & numerical data
Oxcarbazepine
/ adverse effects
Young Adult
Carbamazepine
Clinical practice
Epilepsy
Eslicarbazepine acetate
Euro-Esli
Oxcarbazepine
Journal
Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
15
11
2019
revised:
19
12
2019
accepted:
21
12
2019
pubmed:
26
1
2020
medline:
18
11
2020
entrez:
26
1
2020
Statut:
ppublish
Résumé
To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by analysing data from the Euro-Esli study. Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments included responder rate (≥50 % seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit), assessed after 3, 6 and 12 months of ESL treatment, and at the last visit. Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively. Data were analysed for cohorts of patients who transitioned from carbamazepine and oxcarbazepine to ESL either due to lack of efficacy or poor tolerability. Euro-Esli included 2058 patients, of whom 233 (11.3 %) transitioned from carbamazepine to ESL and 134 (6.5 %) transitioned from oxcarbazepine to ESL. After 12 months of ESL treatment, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n = 163) were 70.0 % and 30.9 %, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n = 90) were 57.1 % and 25.0 %, respectively. Among patients who transitioned from carbamazepine and oxcarbazepine to ESL due to poor tolerability (n = 64 and n = 61, respectively), 26.6 % and 39.5 % experienced AEs, and 8.3 % and 6.8 % discontinued ESL due to AEs, respectively. ESL was efficacious and generally well tolerated in patients transitioning from carbamazepine or oxcarbazepine in clinical practice due to inadequate seizure control or intolerable AEs with these agents.
Identifiants
pubmed: 31981862
pii: S1059-1311(19)30781-2
doi: 10.1016/j.seizure.2019.12.022
pii:
doi:
Substances chimiques
Anticonvulsants
0
Dibenzazepines
0
Carbamazepine
33CM23913M
eslicarbazepine acetate
BEA68ZVB2K
Oxcarbazepine
VZI5B1W380
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-128Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest RR is a consultant for Eisai, Bial, UCB, GlaxoSmithKline and Shire, and receives grant and research support from Bial, Eisai, and UCB. JP has participated in clinical trials for Eisai, UCB, and Bial; received research grants from Eisai, Medtronic, UCB, and Cyberonics; received speaker honoraria from Cyberonics, Eisai, Medtronic, Orion Pharma, and UCB; received support for travel to congresses from Cyberonics, Eisai, Medtronic, and UCB; and participated in advisory boards for Cyberonics, Eisai, Medtronic, UCB, and Pfizer. GA has no conflicts of interest. RM is a current employee of Eisai Europe Ltd. VV has participated in advisory boards and pharmaceutical industry-sponsored symposia for Eisai, UCB Pharma, Bial, Pfizer, GSK, Esteve, Novartis and GW Pharma.